Investigation of barriers to clinical practice guideline-recommended pharmacotherapy in the treatment of COPD

Pharmacy Practice

Volumn 5, Issue 2, 2007, Pages 74-77

  Price, Lea ^a   Billups, Sarah J ^a,b   Rice, Melissa A ^a,b   Hartsfield, Cynthia ^b,c  

^a KAISER PERMANENTE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c CLINICAL RESEARCH UNIT   (United States)

Author keywords

Chronic obstructive; Drug therapy; Patient compliance; Practice guidelines; Pulmonary Disease; United States

Indexed keywords

BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; IPRATROPIUM BROMIDE;

ADULT; AGED; ANAMNESIS; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COHORT ANALYSIS; ELECTRONIC MEDICAL RECORD; FEMALE; HEALTH MAINTENANCE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PRACTICE GUIDELINE; PRESCRIPTION; RETROSPECTIVE STUDY; SPIROMETRY;

EID: 34548131587     PISSN: None     EISSN: 18863655     Source Type: Journal    
DOI: 10.4321/S1886-36552007000200004     Document Type: Article

References (17)

1. National Heart, Lung, and Blood Institute/Worid Health Organization. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report- Executive Summary. 2005. Available at: www.goldcopd.com. (Accessed December 12 2006).
2. National Institutes of Health: National Heart, Lung, and Blood Institute. Chronic obstructive pulmonary disease. NIH Publication 03-5229, 2003 March. Available at: http://www.nhlbi.nih.gov/health/ public/lung/other/copd_fact.pdf. (Accessed August 15,2006).
3. American Thoracic Society; Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1995;152:S77-S121.
4. Siafakas NM, Vermeire P, Pride NB, Paoletti P, Gibson J, Howard P, Yemault JC, Decramer M, Higenbottam T, Postma DS, at al. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J. 1995;8:1398-1420.
5. National Heart, Lung, and Blood Institute/World Health Organization. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease. NHLBI/WHO Workshop Report-Executive Summary. 2001. Available from: www.goldcopd.com. (Accessed December 12,2006)
6. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatrnent of COPD. Chest 1999;115:957-65.
7. Ulrik C. Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomized, double blind, placebo controlled, crossover study. Thorax. 1995;50:750-4.
8. Matheson MC, Abeysena C, Raven JM, Skoric B, Johns DP, Abramson MJ, Walters EH. How have we been managing chronic obstructive pulmonary disease in Australia? Int Med J 2006;36(2):92-9.
9. Lindenauer PK, Pekow P, Gao S, Crawford AS, Guierrez B, Bejamin EM. Quality of care for patients hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 2006;144:894-903.
10. Harvey PA, Murphy MC, Domom E, Berlowitz DJ, Lim WK, Jackson B. Implementing evidence-based guidelines: inpatient management of chronic obstructive pulmonary disease. Intern Med J 2005;35:151-5.
11. Takahashi T, Ichinose M, Inoue H, Shirato K, Hattori T, Takishima T. Underdiagnosis and undertreatment of COPD in primary care settings. Respirology 2003;8:504-8.
12. Rand CS, Nides M, Cowles MK, Wise RA, Connett J. Lung Health Study. Long-term metered-dose inhaler adherence in a clinical trial. Am J Respir Crit Care Med 1995;152:580-8.
13. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication nonadherence impatients with COPD. Chest 2005;128:3198-3204.
14. Brand C, Landgren F, Hutchinson A, Jones C, MacGregor L, Campbell D. Clinical practice guidelines: barriers to durability after effective early implementation. Intern Med J. 2005;35:1162-9.
15. Hartsfield CL, Shetterty S, Palen TE, McCoy M, Marton JP. COPD: Treatment and utilization patterns in managed care. Am J Respir Crit Care Med 2005 [Abstract #A541].
16. Sandhoff BG, Nies LK, Olson KL, Nash JD, Rasmussen JR, Merenich JA. Clinical pharmacy cardiac risk service for managing patients with coronary artery disease in health maintenance organization. Am J Health Syst Pharm 2007;64:77-84.
17. Witt DM, Sadler MA, Shanahan RL, Mazzoli G, Tillman DJ. Effed of a centralized clinical pharmacy anticoagulation service on the outcomes of anticoagulation therapy. Chest 2005;127:1515-22.